Fresenius SE & Co. KGaA Stock
€27.33
Your prediction
Fresenius SE & Co. KGaA Stock
Fresenius is a German healthcare company listed on the Frankfurt and New York stock exchanges under the symbol FSNUF. The company is primarily engaged in the production and distribution of medical devices, pharmaceuticals, and services related to renal dialysis, critical care, and hospital operations. With over 290,000 employees and operations in more than 100 countries, Fresenius is one of the largest healthcare providers in the world. The company has experienced steady growth over the years, driven by its innovative product portfolio, strategic acquisitions, and a focus on operational efficiency.
Pros and Cons of Fresenius SE & Co. KGaA in the next few years
Pros
Cons
Performance of Fresenius SE & Co. KGaA vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Fresenius SE & Co. KGaA | 0.070% | 2.643% | 10.754% | 6.627% | -3.752% | -31.252% | -45.176% |
| Fresenius SE & Co. KGaA ADR | -2.210% | 0.741% | 12.397% | 8.800% | -2.857% | -30.964% | -44.715% |
| Fresenius Medical Care AG & Co KGaA ST | -0.560% | 3.988% | 8.183% | -10.678% | -0.079% | -41.902% | -47.428% |
| Quest Diagnostics Inc. | 0.700% | 8.707% | 7.795% | -3.706% | 3.376% | 18.635% | 53.022% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.As a professional financial analyst, it is imperative to delve into the financials of Fresenius (FSNUF) to uncover insights about the company's performance in the Healthcare Providers & Services industry. At first glance, it is apparent that the company has shown some growth in terms of overall assets and revenue, as well as maintaining a stable financial base. However, a comprehensive assessment requires a deeper analysis of the available data to identify potential pros and cons.
Steady asset growth: Over the years, Fresenius has shown a consistent increase in its total assets. Comparing the years 2020, 2021, and 2022, the total assets have risen from €66.65 billion to €71.96 billion, and finally to €76.41 billion. This growth indicates a positive trajectory in the company's financial position and its ability to expand its reach within the industry.
Revenue growth: Fresenius’s total revenue in its fourth-quarter 2022 financial report reached €10.64 billion. This is a commendable figure for companies in the healthcare sector, and this growth directly influences Fresenius's investment potential.
Comments
News
EQS-AGM: Fresenius SE & Co. KGaA: Announcement of the Convening of the General Meeting in Frankfurt am Main on 17.05.2024 according to article 121 AktG (German Stock Companies Act) with the objective of Europe-wide distribution
EQS-Adhoc: Fresenius SE & Co. KGaA: Fresenius retains relief payments for hospitals of up to €300 million (from the current perspective) and is therefore subject to a ban on dividends and bonuses for 2023